RS Research is a clinical-stage biotechnology start-up developing next generation nanomedicines based on innovative drug delivery platform Sagitta® for targeted chemotherapy.
The company has 5 drug candidates, with different indications in oncology. The most advanced one has completed pre-clinical phase and started Phase-I clinical trial in NSCLC.
Following its 2 million EUR seed investment in 2017, RS Research announced the closing of Series-A investment round worth 12 million USD in December 2021.
The company has 5 drug candidates, with different indications in oncology. The most advanced one has completed pre-clinical phase and started Phase-I clinical trial in NSCLC.
Following its 2 million EUR seed investment in 2017, RS Research announced the closing of Series-A investment round worth 12 million USD in December 2021.
Location: Turkey, Marmara Region, Istanbul
Employees: 51-200
Total raised: $1.18M
Founded date: 2015
Investors 2
| Date | Name | Website |
| 28.03.2023 | ACT Ventur... | act-vc.com |
| - | Eczacıbaşı... | eczacibasi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.04.2017 | - | $1.18M | - |
Mentions in press and media 2
| Date | Title | Description |
| 12.08.2026 | How research partnerships under the MSCA are driving innovation | Companies that receive funding from the EU’s Marie Skłodowska-Curie Actions (MSCA) can take part in initiatives that have a major impact on innovation – in some instances securing nearly one patent per funded project. Over the past 30 years... |
| 21.04.2017 | RS Research Raises €1.1M in Venture Capital Funding | RS Research, a Teknopark Istanbul, Turkey-based nanomedicine startup, raised €1.1m in funding. Technology focused venture capital fund ACT Venture Partners, whose main backer is the European Investment Fund (EIF), provided the funds. The co... |